Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection (NCT05413850)
An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Biogenix Molecular LLC — Miami, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- Biogenix Molecular LLC — Miami, Florida
- NovaCure Health — Miami, Florida
- Emory University Hospital — Atlanta, Georgia
- XCancer Omaha / Urology Cancer Center — Omaha, Nebraska
- Weill Cornell Medicine - New York - Presbyterian Hospital — New York, New York
- Saint Luc University Hospital — Brussels,
- University Hospital Ghent — Ghent,
- University Hospital Leuven — Leuven,
- University Hospital Aachen — Aachen,
- Universitätsklinikum Augsburg — Augsburg,
- University Hospital Essen — Essen,
- Hospital Rechts der Isar — Munich,
- Radboud UMC — Nijmegen, Gelderland
- Meander Medisch Centrum — Amersfoort,
- Bristol Hematology and Oncology Center — Bristol,
- Beatson West of Scotland Cancer Center — Glasgow,
- St Bartholomew's Hospital — London,
- James Cook University Hospital — Middlesbrough,
- Oxford University Hospitals NHS Foundation Trust — Oxford,
- Weston Park — Sheffield,
- University Hospital Southampton NHS Foundation Trust — Southampton,
📞 Contact the Study Coordinator
Phone: +44 (0)1865 634500
Email: contact@blueearthTx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.